TY - JOUR
T1 - Gold(III) bis-thiosemicarbazonato complexes
T2 - synthesis, characterization, radiochemistry and X-ray crystal structure analysis
AU - Bottenus, Brienne N.
AU - Kan, Para
AU - Jenkins, Tyler
AU - Ballard, Beau
AU - Rold, Tammy L.
AU - Barnes, Charles
AU - Cutler, Cathy
AU - Hoffman, Timothy J.
AU - Green, Mark A.
AU - Jurisson, Silvia S.
N1 - Funding Information:
US Department of Energy grant DE-FG07-02ID14380 (for Au-198); University of Missouri Research Reactor Center; University of Missouri Mass Spectrometry Facility; University of Missouri Life Sciences Pre-doctoral Fellowship (BNB); USVA Merit Award (TJH) (biological studies).
PY - 2010/1
Y1 - 2010/1
N2 - Introduction: A variety of (bis)thiosemicarbazone-based ligand systems have been investigated as chelating agents for Au(III) complexes with potential radiotherapeutic applications. Ligand systems containing an ethyl, propyl or butyl backbone between the two imine N donors have been synthesized to evaluate chelate ring size effects on the resultant Au(III) complex stability at the macroscopic and radiotracer levels. Methods: The Au(III) complexes were synthesized and characterized by NMR, electrospray ionization mass spectra, elemental analysis and X-ray crystallography. The 198Au complexes were evaluated in vitro at the tracer level for stability in phosphate-buffered saline at pH 7.4 and 37°C. One of these complexes [198Au(3,4-HxTSE)] showed high in vitro stability and was further evaluated in vivo in normal mice. Results: [Au(ATSM)]AuCl4·2CH3OH, (ATSM=diacetyl-bis(N4-methylthiosemicarbazone)) H14C8N6O2S2Cl 4Au2·2CH3OH, crystallized from methanol in the monoclinic space group P21/n with a=14.7293(13) Å, b=7.7432(7) Å, c=20.4363(18) Å, β=100.140(2)°, V=2294.4 (4) Å3, Z=4; [Au(3,4-HxTSE)]Cl·CH3CH2OH/AuCl2 , (3,4-HxTSE=3,4-hexanedione-bis(N4-ethylthiosemicarbazone)) H26C13.6N6O0.8S2C l1.2Au1.2, crystallized from ethanol in the monoclinic space group P21/c with a=10.1990(10) Å, b=13.8833(14) Å, c=15.1752(15) Å, β=99.353(2)°, V=2120.2 (4) Å3, Z=4. Conclusions: These studies revealed poor stability of the [198Au][Au(3,4-HxTSE)]+ complex; however, crystal structure data suggest potential alterations to the ligand backbone may increase stability.
AB - Introduction: A variety of (bis)thiosemicarbazone-based ligand systems have been investigated as chelating agents for Au(III) complexes with potential radiotherapeutic applications. Ligand systems containing an ethyl, propyl or butyl backbone between the two imine N donors have been synthesized to evaluate chelate ring size effects on the resultant Au(III) complex stability at the macroscopic and radiotracer levels. Methods: The Au(III) complexes were synthesized and characterized by NMR, electrospray ionization mass spectra, elemental analysis and X-ray crystallography. The 198Au complexes were evaluated in vitro at the tracer level for stability in phosphate-buffered saline at pH 7.4 and 37°C. One of these complexes [198Au(3,4-HxTSE)] showed high in vitro stability and was further evaluated in vivo in normal mice. Results: [Au(ATSM)]AuCl4·2CH3OH, (ATSM=diacetyl-bis(N4-methylthiosemicarbazone)) H14C8N6O2S2Cl 4Au2·2CH3OH, crystallized from methanol in the monoclinic space group P21/n with a=14.7293(13) Å, b=7.7432(7) Å, c=20.4363(18) Å, β=100.140(2)°, V=2294.4 (4) Å3, Z=4; [Au(3,4-HxTSE)]Cl·CH3CH2OH/AuCl2 , (3,4-HxTSE=3,4-hexanedione-bis(N4-ethylthiosemicarbazone)) H26C13.6N6O0.8S2C l1.2Au1.2, crystallized from ethanol in the monoclinic space group P21/c with a=10.1990(10) Å, b=13.8833(14) Å, c=15.1752(15) Å, β=99.353(2)°, V=2120.2 (4) Å3, Z=4. Conclusions: These studies revealed poor stability of the [198Au][Au(3,4-HxTSE)]+ complex; however, crystal structure data suggest potential alterations to the ligand backbone may increase stability.
KW - Bis-thiosemicarbazones
KW - Gold(III)
KW - Gold-198
KW - Gold-199
UR - https://www.scopus.com/pages/publications/72949114282
U2 - 10.1016/j.nucmedbio.2009.08.003
DO - 10.1016/j.nucmedbio.2009.08.003
M3 - Article
C2 - 20122667
AN - SCOPUS:72949114282
SN - 0969-8051
VL - 37
SP - 41
EP - 49
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 1
ER -